David M. Simpson
14Patents
6h-index
22Co-inventors
66Inventor score
Filing activity: Sep 17, 1993 → Feb 16, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6218519A | Compounds and methods for the selective treatment of cancer and bacterial infections | Chemistry; Metallurgy | 90 | Expired |
| US6346599B1 | Biodegradable lactone copolymers | Emerging Cross-Sectional Technologies | 21 | Expired |
| US6297349A | Condensation copolymers having supressed crystallinity | Chemistry; Metallurgy | 15 | Expired |
| US6258360A | Prodrugs activated by targeted catalytic proteins | Physics | 12 | Expired |
| US5597573A | Lipid-A analogs: new monosaccharide and disaccharide intermediates for eliciting therapeutic antibodies and for antitumor and antiviral activities | Human Necessities | 11 | Expired |
| US5593969A | Lipid-A analogs: monosaccharide and dissaccharide compounds for inhibiting binding of lipid A receptors to lipid A receptors | Human Necessities | 10 | Expired |
| US6702705B1 | Prodrugs activated by targeted catalytic proteins | Physics | 5 | Expired |
| US10030015B2 | Amine compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity | Emerging Cross-Sectional Technologies | 2 | Active |
| US5891648A | Reaction-based selection for expression of and concentration of catalytic moieties | Physics | 2 | Expired |
| US6121007A | Reaction-based selection for expression of and concentration of catalytic moieties | Physics | 1 | Expired |
| US10934284B2 | Aminoquinazoline compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity | Emerging Cross-Sectional Technologies | 1 | Active |
| US5631137A | Reaction-based selection for expression of and concentration of catalytic moieties | Physics | 1 | Expired |
| US6177270A | Reaction-based selection for expression of and concentration of catalytic moieties | Physics | 1 | Expired |
| US12139483B2 | Imidazoquinolyl compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.